V Stearns

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi CYP2D6 genotype and tamoxifen response
    James M Rae
    Breast Cancer Res 7:E6. 2005
  2. ncbi A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer
    Vered Stearns
    Department of Medicine, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA
    Clin Cancer Res 9:124-33. 2003
  3. ncbi Preclinical and clinical evaluation of intraductally administered agents in early breast cancer
    Vered Stearns
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Sci Transl Med 3:106ra108. 2011
  4. ncbi Management of hot flashes in breast cancer survivors and men with prostate cancer
    Vered Stearns
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M53, Baltimore, MD 21231 1000, USA
    Curr Oncol Rep 6:285-90. 2004
  5. ncbi New therapeutic approaches for hot flashes in women
    Vered Stearns
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231 1000, USA
    J Support Oncol 1:11-21; discussion 14-5, 19-21. 2003
  6. ncbi Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
    Vered Stearns
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231 1000, USA
    Expert Rev Mol Med 10:e34. 2008
  7. ncbi Clinical update: new treatments for hot flushes
    Vered Stearns
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Lancet 369:2062-4. 2007
  8. ncbi A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity
    Vered Stearns
    Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Clin Cancer Res 10:8332-40. 2004
  9. ncbi Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial
    Vered Stearns
    Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA
    J Clin Oncol 23:6919-30. 2005
  10. ncbi Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants
    Vered Stearns
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Nat Rev Cancer 6:886-93. 2006

Detail Information

Publications70

  1. ncbi CYP2D6 genotype and tamoxifen response
    James M Rae
    Breast Cancer Res 7:E6. 2005
  2. ncbi A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer
    Vered Stearns
    Department of Medicine, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA
    Clin Cancer Res 9:124-33. 2003
    ....
  3. ncbi Preclinical and clinical evaluation of intraductally administered agents in early breast cancer
    Vered Stearns
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Sci Transl Med 3:106ra108. 2011
    ..If successful, administration of agents directly into the ductal system may allow for "breast-sparing mastectomy" in select women...
  4. ncbi Management of hot flashes in breast cancer survivors and men with prostate cancer
    Vered Stearns
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M53, Baltimore, MD 21231 1000, USA
    Curr Oncol Rep 6:285-90. 2004
    ..However, such hormonal therapies as depomedroxyprogesterone acetate can be prescribed for an informed individual who experiences bothersome symptoms despite nonhormonal treatments...
  5. ncbi New therapeutic approaches for hot flashes in women
    Vered Stearns
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231 1000, USA
    J Support Oncol 1:11-21; discussion 14-5, 19-21. 2003
    ..We will focus on nonhormonal treatments that have been studied in prospective randomized clinical trials, and will present an algorithm for the treatment of symptomatic patients...
  6. ncbi Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
    Vered Stearns
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231 1000, USA
    Expert Rev Mol Med 10:e34. 2008
    ....
  7. ncbi Clinical update: new treatments for hot flushes
    Vered Stearns
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Lancet 369:2062-4. 2007
  8. ncbi A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity
    Vered Stearns
    Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Clin Cancer Res 10:8332-40. 2004
    ..We chose tamoxifen to establish proof of principal with a known effective agent...
  9. ncbi Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial
    Vered Stearns
    Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA
    J Clin Oncol 23:6919-30. 2005
    ..A secondary objective was to evaluate quality of life (QOL) parameters...
  10. ncbi Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants
    Vered Stearns
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Nat Rev Cancer 6:886-93. 2006
    ..Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions...
  11. ncbi Pharmacogenetics in the treatment of breast cancer
    V Stearns
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Pharmacogenomics J 4:143-53. 2004
  12. ncbi More choices, more questions: weighing the options for treating hot flashes
    Vered Stearns
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231-1000, USA
    J Support Oncol 4:323-5. 2006
  13. ncbi Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole
    Tatiana M Prowell
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Prev Res (Phila) 4:1993-2001. 2011
    ....
  14. ncbi Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial
    Vered Stearns
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    JAMA 289:2827-34. 2003
    ..Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective...
  15. ncbi Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
    Stephanie Gaillard
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRBI, Room 144, Baltimore, MD 21231, USA
    Breast Cancer Res 13:205. 2011
    ..Recent advances have been made in identifying potential mechanisms underlying these effects. Adequate management of symptoms may enhance patient adherence to therapy, thereby improving breast cancer-related outcomes...
  16. ncbi Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results
    D F Hayes
    Department of Internal Medicine and Breast Oncology Program, Comprehensive Cancer Center, University of Michigan Health and Hospitals System, Ann Arbor, Michigan, USA
    Clin Pharmacol Ther 88:626-9. 2010
    ....
  17. ncbi Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy
    N L Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Br J Cancer 102:294-300. 2010
    ..We hypothesised that inherited variants in candidate genes involved in oestrogen signalling and tamoxifen metabolism might be associated with tamoxifen effects in bone...
  18. ncbi Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age
    Z Desta
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    Clin Pharmacol Ther 90:693-700. 2011
    ..CYP2A6 metabolic status, along with BMI and age, may serve as a biomarker of the efficacy of letrozole treatment or a predictor of adverse effects...
  19. ncbi Drug interactions and pharmacogenomics in the treatment of breast cancer and depression
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 300 North Ingalls St, Bldg. 3A04, Ann Arbor, MI 48109-5419, USA
    Am J Psychiatry 165:1251-5. 2008
  20. ncbi Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study
    N L Henry
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical School, 300 North Ingalls, North Ingalls Building 3A04, Ann Arbor, MI 48109 5419, USA
    Br J Cancer 103:291-6. 2010
    ..Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers...
  21. ncbi Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
    J M Rae
    Breast Oncology Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0612, USA
    Pharmacogenomics J 9:258-64. 2009
    ..Therefore, patients who may be most likely to benefit from tamoxifen may paradoxically be most likely to discontinue treatment prematurely...
  22. ncbi When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer
    H Yamauchi
    Breast Cancer Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    J Clin Oncol 19:2334-56. 2001
    ....
  23. ncbi Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
    Vered Stearns
    The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Natl Cancer Inst 95:1758-64. 2003
    ..Coadministration of paroxetine decreased the plasma concentration of endoxifen. Our data suggest that CYP2D6 genotype and drug interactions should be considered in women treated with tamoxifen...
  24. ncbi Approach to menopausal symptoms in women with breast cancer
    Vered Stearns
    The Breast Cancer Program, University of Michigan Comprehensive Cancer Center, 6303 Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0942, USA
    Curr Treat Options Oncol 3:179-90. 2002
    ..Selective serotonin re-uptake inhibitors should be considered as a first-line nonhormonal pharmacologic therapy for women with menopausal symptoms...
  25. ncbi CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    Yan Jin
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Natl Cancer Inst 97:30-9. 2005
    ....
  26. ncbi New prognostic factors for breast cancer recurrence
    C Isaacs
    Breast Cancer Program, Lombardi Cancer Center, Georgetown University, Washington, DC, USA
    Semin Oncol 28:53-67. 2001
    ..This article provides an overview of issues that need to be considered when analyzing studies of prognostic factors, as well as a review of the currently recognized and the newer candidate prognostic factors...
  27. ncbi Prognostic factors in breast cancer: current and new predictors of metastasis
    D F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109 0942, USA
    J Mammary Gland Biol Neoplasia 6:375-92. 2001
    ..This paper provides an overview of issues that need to be considered when analyzing studies of prognostic factors as well as a review of the currently recognized and the newer candidate prognostic factors...
  28. ncbi Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Breast Cancer Res Treat 117:571-5. 2009
    ..062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy...
  29. ncbi Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
    Michaela J Higgins
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231 1000, USA
    J Natl Compr Canc Netw 7:203-13. 2009
    ....
  30. ncbi Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer
    Saranya Chumsri
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21231, USA
    Clin Breast Cancer 10:40-5. 2010
    ..We evaluated pathologic complete response (pCR) rate and cardiac safety of preoperative doxorubicin and cyclophosphamide followed by a taxane with or without trastuzumab...
  31. ncbi Treatment strategies for hot flushes
    Wen Shen
    Johns Hopkins University School of Medicine, Division of Gynecology, 600 North Wolfe Street, Phipps 249, Baltimore, MD 21287, USA
    Expert Opin Pharmacother 10:1133-44. 2009
    ..Recommendation at this time is for the shortest duration of therapy, which means that episodic review of therapy is indicated...
  32. ncbi Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer
    Richard C Zellars
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins, 401 N Broadway, Suite 1440, Baltimore, MD 21231, USA
    J Clin Oncol 27:2816-22. 2009
    ..We hypothesized that anthracycline-based chemotherapy and concurrent partial breast irradiation (PBI) is safe and conducted a single-arm feasibility trial testing this hypothesis with dose-dense doxorubicin and cyclophosphamide (ddAC)...
  33. ncbi Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:5911-8. 2009
    ..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer...
  34. ncbi CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance
    Michaela J Higgins
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRBI, Room 145, Baltimore, MD 21231, USA
    Curr Oncol Rep 12:7-15. 2010
    ..This review summarizes the literature to date with a focus on clinically relevant recent studies that examined the association between CYP2D6 polymorphisms and tamoxifen-associated outcomes...
  35. ncbi Intraductal therapy for the prevention of breast cancer
    Lisa Jacobs
    Johns Hopkins University, 600 North Wolfe Street, Osler 624, Baltimore, MD 21287, USA
    Curr Opin Investig Drugs 11:646-52. 2010
    ..As a result of these advances, intraductal treatment in high-risk populations is being investigated in clinical trials...
  36. ncbi A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231-2410, USA
    Hum Gene Ther 15:313-37. 2004
  37. ncbi Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT
    Heather A Jacene
    Division of Nuclear Medicine, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Clin Nucl Med 31:379-81. 2006
    ..This case highlights the importance of clinical history and laboratory correlation for the proper interpretation of FDG PET scans...
  38. ncbi Hot flushes
    Vered Stearns
    Breast Oncology Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Georgetown, USA
    Lancet 360:1851-61. 2002
    ..Moreover, the efficacy of these drugs provides new insight into the pathophysiology of hot flushes. In this critical review, we assess knowledge of the epidemiology, pathophysiology, and treatment of hot flushes...
  39. ncbi Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen
    N I Ntukidem
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    Clin Pharmacol Ther 83:702-10. 2008
    ..002; gene-dose effect) and high-density lipoprotein (P=0.004; gene-dose effect). Our results suggest that estrogen receptor genotyping may be useful in predicting which women would benefit more from tamoxifen...
  40. ncbi A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia
    Vered Stearns
    Breast Cancer Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C, USA
    Clin Cancer Res 10:7583-91. 2004
    ..Further investigations must overcome logistical obstacles to accrual, and they must focus on approaches to maximize tissue collection and to incorporate genomic analysis of target lesions...
  41. ncbi Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment
    Silvana Borges
    Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Pharmacol Ther 80:61-74. 2006
    ..We conducted a prospective trial in 158 patients with breast cancer who were taking tamoxifen to further understand the effect of CYP2D6 genotype and concomitant medications on endoxifen plasma concentrations...
  42. ncbi Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond
    Ting Bao
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231-1000, USA
    Am J Ther 13:337-48. 2006
    ....
  43. ncbi A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer. Challenges and opportunities
    Roisin Connolly
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231 1000, USA
    Oncology (Williston Park) 24:135-43. 2010
    ....
  44. ncbi The Role of c-erbB-2 as a predictive factor in breast cancer
    H Yamauchi
    Breast Cancer Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Breast Cancer 8:171-83. 2001
    ..Importantly, c-erbB-2 status appears critical for selecting patients who should receive trastuzumab. Well-designed prospective randomized clinical trials or formal meta-analysis will help to establish the predictive role of c-erbB-2...
  45. ncbi Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy
    Yan Jin
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 26:5849-54. 2008
    ..We determined whether genetic polymorphisms in estrogen receptors (ESRs) alpha and beta (ESR1 and ESR2, respectively) are associated with tamoxifen-induced hot flashes...
  46. ncbi Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management
    N Lynn Henry
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Medical School, Ann Arbor, Michigan 48109 5419, USA
    Oncology (Williston Park) 22:1401-8. 2008
    ..Increased knowledge about the etiology and management of this clinically important toxicity could potentially improve patient adherence to AI therapy, thereby leading to a reduction in breast cancer recurrence and death...
  47. ncbi Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies
    Heather A Jacene
    Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland, USA
    J Nucl Med 47:950-6. 2006
    ..These profound alterations in (18)F-FDG biodistribution induced by pegfilgrastim must be considered when one is evaluating quantitative (18)F-FDG PET scans for tumor response to therapy...
  48. ncbi The biology of hormone refractory breast and prostate cancer: An NCI workshop report
    Suresh Mohla
    Division of Cancer Biology, National Cancer Institute, Bethesda, MD, USA
    Cancer Biol Ther 8:1975-85. 2009
    ....
  49. ncbi Concordance of cancer patients' function, symptoms, and supportive care needs
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 18:991-8. 2009
    ..Although patients' function, symptoms, and supportive care needs are obviously related, a better understanding of these relationships could improve patient management...
  50. ncbi A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 5419, USA
    Cancer 116:4360-7. 2010
    ..Tendon sheath fluid and tenosynovial changes have been demonstrated by imaging symptomatic patients who were treated with AIs. The authors hypothesized that these abnormalities are correlated with AIMSS...
  51. ncbi Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer
    Vered Stearns
    Breast Cancer Program, Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
    Ann Surg Oncol 9:235-42. 2002
    ..Sentinel lymphadenectomy (SL) is accepted for axillary evaluation in early breast cancer. We assessed the feasibility and predictive value of SL after neoadjuvant chemotherapy...
  52. ncbi Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30
    Claire F Snyder
    Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
    Qual Life Res 19:837-45. 2010
    ..We explored using needs assessments to identify HRQOL scores associated with patient-reported unmet needs...
  53. ncbi Epigenetic regulation as a new target for breast cancer therapy
    Vered Stearns
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Invest 25:659-65. 2007
  54. ncbi Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors
    N Lynn Henry
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0942, USA
    Breast Cancer Res Treat 111:365-72. 2008
    ..AIs are commonly associated with musculoskeletal symptoms. The primary objective of this study was to describe the musculoskeletal symptoms that developed in the first 100 subjects enrolled who had at least 6 months follow-up...
  55. ncbi Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications
    Michael A Jacobs
    The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Technol Cancer Res Treat 3:543-50. 2004
    ..A combination of MR, MRSI, and 23Na sodium MR parameters may be examined in a single MR imaging examination, potentially resulting in improved specificity for radiologic evaluation of malignancy...
  56. ncbi Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI
    Ronald Ouwerkerk
    Division of MR Research, Russel H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21287 0845, USA
    Breast Cancer Res Treat 106:151-60. 2007
    ....
  57. ncbi Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support
    Antonio C Wolff
    J Clin Oncol 24:2392-4; author reply 2394-5. 2006
  58. ncbi Cooling off hot flashes
    Vered Stearns
    J Clin Oncol 20:1436-8. 2002
  59. ncbi Déjà vu for breast cancer two?
    Vered Stearns
    J Natl Cancer Inst 96:497-9. 2004
  60. ncbi Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors
    Gary Elkins
    Mind Body Cancer Research Program, Scott and White Memorial Hospital, Temple, TX, USA
    Psychooncology 16:487-92. 2007
    ..A randomized, controlled clinical trial is planned to more definitively elucidate the efficacy and applicability of hypnosis for reducing hot flashes...
  61. ncbi Centrally active nonhormonal hot flash therapies
    Charles L Loprinzi
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Med 118:118-23. 2005
    ..The most efficacious and clinically appropriate agents for use are newer antidepressants and gabapentin. Continued evaluation of the efficacy and toxicity of these agents is ongoing...
  62. ncbi Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
    Manfred Kaufmann
    Department of Obstetrics and Gynecology, J W Goethe University Hospital, Frankfurt, Germany
    J Clin Oncol 24:1940-9. 2006
    ..As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined...
  63. ncbi Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors
    Gary Elkins
    Department of Psychology and Neuroscience, Baylor University, Waco, TX 76798, USA
    J Clin Oncol 26:5022-6. 2008
    ..A well-tolerated and effective mind-body treatment for hot flashes would be of great value. On the basis of previous case studies, this study was developed to evaluate the effect of a hypnosis intervention for hot flashes...
  64. ncbi Can hypnosis reduce hot flashes in breast cancer survivors? A literature review
    Gary Elkins
    Scott and White Hospital and Clinic, Temple, TX 76508, USA
    Am J Clin Hypn 47:29-42. 2004
    ..However this intervention has not been adequately studied. We discuss an NIH-funded randomized clinical trial of hypnosis for hot flashes in breast cancer survivors that is presently being conducted...
  65. ncbi A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
    Daniel F Hayes
    J Natl Cancer Inst 100:610-3. 2008
  66. ncbi Adjuvant aromatase inhibitors and emerging quality-of-life considerations
    Susanne Briest
    Expert Rev Anticancer Ther 8:1-4. 2008
  67. ncbi Chemotherapeutic Strategies for advanced breast cancer
    Susanne Briest
    University of Leipzig Department of Gynecology and Obstetrics Leipzig, Germany
    Oncology (Williston Park) 21:1325-35; discussion 1338, 1340. 2007
    ..In this review, we will provide an update on commonly used chemotherapy-based regimens for the treatment of metastatic breast cancer, with a focus on tailoring therapy to different subtypes of the disease...
  68. ncbi Lipophilic statins merit additional study for breast cancer chemoprevention
    Tatiana M Prowell
    J Clin Oncol 24:2128-9; author reply 2129. 2006
  69. ncbi Role of CYP2D6 testing in selection of endocrine therapy for breast cancer
    Justin Stebbing
    Pharmacogenomics 8:1-3. 2007
  70. ncbi Extended adjuvant therapy for breast cancer--how much is enough?
    Tatiana M Prowell
    J Natl Cancer Inst 99:1825-7. 2007